Open-label Safety And Efficacy Evaluation Of Fx-1006a In Subjects With Transthyretin (Ttr) Amyloidosis (fx1a-303)

Trial Profile

Open-label Safety And Efficacy Evaluation Of Fx-1006a In Subjects With Transthyretin (Ttr) Amyloidosis (fx1a-303)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Tafamidis meglumine (Primary)
  • Indications Amyloidosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Aug 2017 Results published in a Pfizer media release.
    • 15 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Aug 2016 According to a Pfizer media release, results of pooled post hoc analysis from this and other two trials (Profiles 19933 and 275556) were published online in Amyloid: The Journal of Protein Folding Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top